EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, RAPT Therapeutics's enterprise value is $9.86 Mil.
RAPT Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, RAPT Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for RAPT Therapeutics's EV-to-Revenue or its related term are showing as below:
During the past 7 years, the highest EV-to-Revenue of RAPT Therapeutics was 879.34. The lowest was -50.90. And the median was 184.16.
RAPT's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.37 * Ranked among companies with meaningful EV-to-Revenue only.
The historical data trend for RAPT Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RAPT Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, RAPT Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RAPT Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RAPT Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where RAPT Therapeutics's EV-to-Revenue falls into.
RAPT Therapeutics's current Enterprise Value is $9.86 Mil.
RAPT Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAPT Therapeutics's share price for today is $4.33.
RAPT Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAPT Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of RAPT Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
RAPT Therapeutics (RAPT Therapeutics) Business Description
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RAPT has been successfully added to your 